- Home
- FRA vs PGEN Comparison
FRA vs PGEN Comparison
Compare FRA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRA
- PGEN
- Stock Information
- Founded
- FRA 2003
- PGEN 1998
- Country
- FRA United States
- PGEN United States
- Employees
- FRA N/A
- PGEN N/A
- Industry
- FRA Investment Bankers/Brokers/Service
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- FRA Finance
- PGEN Health Care
- Exchange
- FRA Nasdaq
- PGEN Nasdaq
- Market Cap
- FRA 466.7M
- PGEN 493.0M
- IPO Year
- FRA N/A
- PGEN N/A
- Fundamental
- Price
- FRA $13.38
- PGEN $4.53
- Analyst Decision
- FRA
- PGEN Buy
- Analyst Count
- FRA 0
- PGEN 5
- Target Price
- FRA N/A
- PGEN $7.50
- AVG Volume (30 Days)
- FRA 165.4K
- PGEN 16.8M
- Earning Date
- FRA 01-01-0001
- PGEN 08-12-2025
- Dividend Yield
- FRA 11.06%
- PGEN N/A
- EPS Growth
- FRA N/A
- PGEN N/A
- EPS
- FRA N/A
- PGEN N/A
- Revenue
- FRA N/A
- PGEN $4,340,000.00
- Revenue This Year
- FRA N/A
- PGEN $253.63
- Revenue Next Year
- FRA N/A
- PGEN $699.64
- P/E Ratio
- FRA N/A
- PGEN N/A
- Revenue Growth
- FRA N/A
- PGEN N/A
- 52 Week Low
- FRA $11.33
- PGEN $0.65
- 52 Week High
- FRA $13.10
- PGEN $4.83
- Technical
- Relative Strength Index (RSI)
- FRA 66.52
- PGEN 85.94
- Support Level
- FRA $13.20
- PGEN $2.94
- Resistance Level
- FRA $13.27
- PGEN $4.30
- Average True Range (ATR)
- FRA 0.06
- PGEN 0.37
- MACD
- FRA 0.01
- PGEN 0.23
- Stochastic Oscillator
- FRA 99.15
- PGEN 99.31
About FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.